SOD1 |
NSC-34 cells |
NA |
Sucrose gradient centrifugation |
Western blot: CD9 |
Gomes et al., 2007
|
SOD1 |
Astrocytes |
NA |
UC |
Electron Microscopy/Western blot: flotillin-1 |
Basso et al., 2013
|
SOD1 |
NSC-34 cells |
NA |
UC |
Electron Microscopy |
Grad et al., 2014
|
SOD1 |
Microglia |
NA |
UC |
Atomic force microscopy (AFM) |
Massenzio et al., 2018
|
SOD1 |
Mouse/human brain and spinal cord tissues |
5 patients; 4 controls |
Sucrose gradient centrifugation |
Western blot: SOD1, PrP, actin, GRP78/Bip, CD9 |
Silverman et al., 2019
|
TDP-43 |
SH-SY5Y cells |
NA |
ExoQuick-TC kit (SBI) |
CD63 |
Nonaka et al., 2013
|
TDP-43 |
CSF |
18 patients; 8 ALS plus FTD patients; 15 controls |
UC |
Western blot: Flotillin 1 |
Ding et al., 2015
|
TDP-43 |
Neuro2a cells and primary neurons brain tissues mouse serum |
3 patients; 3 controls |
UC |
Electron microscopy Western blot: CD63 and ALIX |
Iguchi et al., 2016
|
TDP-43 |
Serum |
18 patients |
Immuno-affinity |
Transmission Electron Microscopy |
Chen et al., 2020
|
FUS |
SH-SY5Y and N2A cells |
NA |
UC |
Western blot: ALIX, TSG101 and CD63 |
Kamelgarn et al., 2016
|
DPR |
NSC-34 cells |
NA |
Total Exosome Isolation kit (Thermo Fisher) |
Western blot: flotillin, TSG101, and CD63 |
Westergard et al., 2016
|
NOC2L |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
PDCD6IP |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
VCAN |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
SERPINA3 |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
PTPRZ1 |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
C1QC |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
CCDC19 |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
MYL6B |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
MARCO |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
FCGBP |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
FOLR1 |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
RELN |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
CFB |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
CHMP4A |
CSF |
3 patients; 3 controls |
SEC |
Western blot analysis: CD9, CD81 Electron microscopy: CD81, CD9, and NIR |
Hayashi et al., 2020
|
Interleukin-6 |
plasma |
40 patients; 39 controls |
Immuno-affinity |
Western blot: CD63 Transmission electron microscope |
Chen Y. et al., 2019
|
STAU1 |
Motor cortex |
10 patients; 5 controls |
Sucrose gradient centrifugation |
Western blot: flotillin-1, TSG101 and syntenin Transmission electron microscopy (TEM) |
Vassileff et al., 2020
|
DHX30 |
Motor cortex |
10 patients; 5 controls |
Sucrose gradient centrifugation |
Western blot: flotillin-1, TSG101 and syntenin Transmission electron microscopy (TEM) |
Vassileff et al., 2020
|
189 proteins |
ASC cells |
NA |
PureExo® Exosome isolation kit |
Transmission electron microscopy (TEM) Western blot: HSP70, CD9, and CD81 |
Bonafede et al., 2019
|